

# Ke-Fei Dou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5011903/publications.pdf>

Version: 2024-02-01

53  
papers

479  
citations

1040056

9  
h-index

794594

19  
g-index

54  
all docs

54  
docs citations

54  
times ranked

552  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic and Practical Validation of ESC/EACTS High Ischemic Risk Definition on Long-Term Thrombotic and Bleeding Events in Contemporary PCI Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 502-526.	2.0	4
2	Integrated coronary disease burden and patterns to discriminate vessels benefiting from percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, .	1.7	9
3	Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12â€‰Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI. <i>Journal of Interventional Cardiology</i> , 2022, 2022, 1-15.	1.2	0
4	Effect of type 2 diabetes on coronary artery ectasia: smaller lesion diameter and shorter lesion length but similar adverse cardiovascular events. <i>Cardiovascular Diabetology</i> , 2022, 21, 9.	6.8	1
5	Intraâ€‰aortic balloon pump in cardiogenic shock: A propensity score matching analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1456-1464.	1.7	3
6	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein in Patients With Previous Myocardial Infarction. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 797297.	2.4	1
7	Impact of Lipoprotein(a) concentrations on long-term cardiovascular outcomes in patients undergoing percutaneous coronary intervention: A large cohort study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1670-1680.	2.6	3
8	Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease. <i>Frontiers in Endocrinology</i> , 2022, 13, 860698.	3.5	0
9	How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?. <i>Journal of the American Heart Association</i> , 2022, 11, e023578.	3.7	6
10	New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS121011536.	3.9	12
11	Prognostic Implications of Pre-stent Pullback Pressure Gradient and Post-stent Quantitative Flow Ratio in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	6
12	Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI. <i>Platelets</i> , 2021, 32, 533-541.	2.3	4
13	Predictors for adverse outcomes of patients with recanalized chronic total occlusion lesion. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13368.	3.4	3
14	Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2021, 142, 14-24.	1.6	2
15	Letter to the Editor: How Should We Treat High-risk Patients in the Chronic Phase Following PCI: Clopidogrel or Prolonged DAPT?. <i>Journal of Korean Medical Science</i> , 2021, 36, e167.	2.5	0
16	Early radial artery occlusion following the use of a transradial <sc>7â€‰French</sc> sheath for complex coronary interventions in Chinese patients. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1063-1071.	1.7	3
17	Longâ€‰term clinical outcomes in transradial versus transfemoral access for left main percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1009-1015.	1.7	0
18	Association of symptom status, myocardial viability, and clinical/anatomic risk on longâ€‰term outcomes after chronic total occlusion percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 996-1008.	1.7	3

#	ARTICLE	IF	CITATIONS
19	Establishing the optimal duration of DAPT following PCI in high-risk TWILIGHT-like patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	1.7	3
20	Global Chronic Total Occlusion Crossing Algorithm. <i>Journal of the American College of Cardiology</i> , 2021, 78, 840-853.	2.8	111
21	Comparison of outcomes for percutaneous coronary intervention in men and women with unprotected left main disease. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 168-174.	0.2	1
22	Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study. <i>Thrombosis Journal</i> , 2021, 19, 90.	2.1	5
23	Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 807925.	2.4	5
24	Assessing the association of appropriateness of coronary revascularization and 1-year clinical outcomes for patients with stable coronary artery disease in China. <i>Chinese Medical Journal</i> , 2020, 133, 1-8.	2.3	9
25	Fuster-BEWAT score versus cardiovascular health score to predict subclinical target organ damage: Insights from a large-scale Asian population. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2292-2295.	1.8	2
26	Prognostic Value of Quantitative Flow Ratio Based Functional SYNTAX Score in Patients With Left Main or Multivessel Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009155.	3.9	19
27	Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention. <i>Chinese Medical Journal</i> , 2020, 133, 2674-2681.	2.3	3
28	Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2020, 133, 61-70.	1.6	5
29	Prognostic significance of occlusion length in recanalized chronic total occlusion lesion: a retrospective cohort study with 5-year follow-up. <i>BMJ Open</i> , 2020, 10, e038302.	1.9	5
30	Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-10.	1.2	7
31	Mis-estimation of coronary lesions and rectification by SYNTAX score feedback for coronary revascularization appropriateness. <i>Chinese Medical Journal</i> , 2020, 133, 1276-1284.	2.3	1
32	Validation of bifurcation DEFINITION criteria and comparison of stenting strategies in true left main bifurcation lesions. <i>Scientific Reports</i> , 2020, 10, 10461.	3.3	12
33	Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 663-675.	2.6	9
34	Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 313.	1.7	5
35	Personalized Early-Warning Signals during Progression of Human Coronary Atherosclerosis by Landscape Dynamic Network Biomarker. <i>Genes</i> , 2020, 11, 676.	2.4	7
36	Cross-sectional study of retroperitoneal hematoma after invasive intervention in a Chinese population: Prevalence, characteristics, management and outcomes. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 2975-2984.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Optimal Strategy for Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation in High-Risk $\alpha$ -TWILIGHT-like Patients With Diabetes Mellitus. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 586491.	2.4	3
38	A retrospective study of an invasive versus conservative strategy in patients aged $\geq 80$ years with acute ST-segment elevation myocardial infarction. <i>Journal of International Medical Research</i> , 2019, 47, 4431-4441.	1.0	2
39	Association between smoking and in-hospital mortality in patients with acute myocardial infarction: results from a prospective, multicentre, observational study in China. <i>BMJ Open</i> , 2019, 9, e030252.	1.9	9
40	Gender differences in treatment strategies among patients $\geq 80$ years old with non-ST-segment elevation myocardial infarction. <i>Journal of Thoracic Disease</i> , 2019, 11, 5258-5265.	1.4	1
41	A novel phenotype with splicing mutation identified in a Chinese family with desminopathy. <i>Chinese Medical Journal</i> , 2019, 132, 127-134.	2.3	9
42	Angiographic characteristics and in-hospital mortality among patients with ST-segment elevation myocardial infarction presenting without typical chest pain. <i>Chinese Medical Journal</i> , 2019, 132, 2286-2291.	2.3	7
43	Relationship of myocardial hibernation, scar, and angiographic collateral flow in ischemic cardiomyopathy with coronary chronic total occlusion. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 1720-1730.	2.1	25
44	Clinical significance of diabetes on symptom and patient delay among patients with acute myocardial infarction-an analysis from China Acute Myocardial Infarction (CAMI) registry. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 395-400.	0.2	4
45	Invasive versus conservative strategy in consecutive patients aged 80 years or older with non-ST-segment elevation myocardial infarction: a retrospective study in China. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 741-748.	0.2	3
46	Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 573-581.	1.7	21
47	The CAMI-score: A Novel Tool derived From CAMI Registry to Predict In-hospital Death among Acute Myocardial Infarction Patients. <i>Scientific Reports</i> , 2018, 8, 9082.	3.3	11
48	Dual-time-point myocardial $^{18}\text{F}$ -FDG imaging in the detection of coronary artery disease. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 120.	1.7	8
49	Costs and Benefits Associated With Transradial Versus Transfemoral Percutaneous Coronary Intervention in China. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	30
50	Clinical and Angiographic Predictors of Major Side Branch Occlusion after Main Vessel Stenting in Coronary Bifurcation Lesions. <i>Chinese Medical Journal</i> , 2015, 128, 1471-1478.	2.3	12
51	Myocardial $^{18}\text{F}$ -FDG Uptake After Exercise-Induced Myocardial Ischemia in Patients with Coronary Artery Disease. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1986-1991.	5.0	59
52	Clinical and angiographic characteristics of premenopausal women with coronary artery disease. <i>Chinese Medical Journal</i> , 2008, 121, 2392-6.	2.3	5
53	Directly Measured vs. Calculated Low-Density Lipoprotein Cholesterol Does Not Identify Additional Individuals With Coronary Artery Disease and Diabetes at Higher Risk of Adverse Events: Insight From a Large Percutaneous Coronary Intervention Cohort in Asia. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9,	2.4	1